NASDAQ:AUPH - Aurinia Pharmaceuticals Inc.
$6.31
 $-0.01
-0.16%
4:00PM EDT
2019-04-18
Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  AUPH     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 47   199. 07   233. 87  
42 stocks rank:  3. 90 K 1. 43 K 1. 06 K
# analyst opinions:  7. 00   14. 48   14. 09  
mean recommendation:  1. 70   2. 09   2. 01  

quick ratio:  17. 36   5. 29   1. 92  
current ratio:  18. 30   5. 64   2. 40  

target price low:  9. 00   84. 50   115. 74  
target price avg:  11. 50   110. 73   137. 39  
target price high:  14. 00   136. 41   157. 80  
1-yr high:  7. 64   114. 11   138. 85  
last close:  6. 31   87. 56   116. 78  
50-day avg:  6. 50   95. 43   123. 53  
200-day avg:  6. 03   94. 13   121. 20  
1-yr low:  5. 08   72. 67   98. 41  
volume:  932. 51 K 2. 43 M 4. 85 M
50-day avg volume:  770. 56 K 2. 72 M 4. 97 M
200-day avg volume:  703. 03 K 2. 90 M 4. 58 M

1-day return:  -0. 16 % -0. 40 % 0. 07 %
this week return:  -1. 71 % -5. 72 % -4. 11 %
12-wk return:  2. 94 % 1. 78 % -0. 04 %
52-wk return:  20. 81 % 10. 81 % 14. 09 %

enterprise value (EV):  462. 45 M 51. 19 B 117. 96 B
market cap:  580. 08 M 43. 00 B 104. 52 B
EBITDA:  -54. 59 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -8. 47   4. 34   13. 27  
enterprise/revenue (EV/R):  998. 81   68. 16   13. 68  
total revenue:  463. 00 K 10. 61 B 38. 24 B
total debt:  0. 00   12. 22 B 16. 66 B
net income (common):  -64. 12 M 2. 20 B 4. 21 B

shares outstanding:  85. 34 M 570. 91 M 1. 24 B
shares:  66. 15 M 571. 02 M 1. 23 B
shares short:  5. 99 M 9. 93 M 16. 79 M
shares short prior month:  5. 96 M 9. 96 M 16. 58 M
short ratio:  7. 10   5. 31   3. 30  
total cash/share:  1. 37   11. 13   9. 30  
total cash:  125. 86 M 6. 70 B 7. 10 B
free cash flow:  -32. 84 M 3. 58 B 4. 74 B
operating cash flow:  -51. 61 M 4. 14 B 6. 32 B

book value:  1. 32   12. 76   26. 84  
price/book:  4. 79   3. 08   -1. 74  
gross profits:  463. 00 K 8. 03 B 34. 77 B
operating margins:  -12129. 16 % -721. 97 % -88. 82 %
EBITDA margins:  0. 00 % 10. 94 % 22. 54 %
profit margins:  0. 00 % 7. 81 % 10. 60 %
gross margins:  0. 00 % 37. 02 % 55. 68 %

1-yr max volatility:  16. 32 % --- ---
1-yr mean volatility:  0. 09 % 0. 03 % 0. 04 %

1-yr EPS:  -0. 76   2. 39   4. 08  
forward EPS:  -0. 55   3. 97   7. 14  
P/E:  -8. 35   13. 59   22. 83  
forward P/E:  -11. 67   -20. 05   14. 49  
PE/G:  2. 53   -1. 46   1. 68  
growth:  -3. 30 % 126. 81 % 29. 29 %
earnings high:  -0. 08   1. 02   1. 63  
earnings avg:  -0. 14   0. 76   1. 51  
earnings low:  -0. 19   0. 47   1. 39  
revenue high:  100. 00 K 2. 68 B 10. 71 B
revenue avg:  40. 00 K 2. 59 B 10. 49 B
revenue low:  -0. 00   2. 49 B 10. 25 B
return on assets:  -20. 91 % -2. 80 % 5. 29 %
return on equity:  -46. 08 % -18. 52 % 7. 38 %
revenue growth:  -3. 30 % 92. 55 % 19. 15 %
revenue/share:  0. 01   13. 27   55. 24  

beta (1yr vs S&P500):  1. 09   1. 24   0. 93  
sharpe (1yr):  0. 49   0. 29   0. 60  


Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : AUPH
.    + 1.756 =         1.756 :: INITIAL WEIGHT
.   + 47.917 =        49.673 :: spline projection addition
.    x 1.432 =        71.132 :: industry recommendation factor
.    x 2.622 =        186.53 :: symbol recommendation factor
.    x 4.908 =       915.417 :: EV/R factor
.    x 0.998 =       913.503 :: return on assets factor
.    x 0.995 =       909.294 :: return on equity factor
.      x 1.0 =       908.994 :: revenue growth factor
.    x 3.403 =      3093.286 :: current ratio factor
.     x 1.03 =      3186.405 :: quick ratio factor
.    x 1.068 =      3403.411 :: short ratio factor
.    x 2.048 =      6969.885 :: price-to-book factor
.    x 1.058 =      7374.568 :: 5-day avg > 200-day avg
.    x 1.078 =      7947.705 :: 50-day avg > 200-day avg
.    x 2.018 =      16035.63 :: P/E weight
.    x 0.793 =     12715.623 :: PE/G factor
.    x 1.711 =     21758.579 :: beta factor
.    x 0.488 =     10627.492 :: sharpe factor
.    x 1.695 =     18017.142 :: target low factor
.    x 1.302 =     23463.845 :: target mean factor
.     x 1.11 =     26054.131 :: target high factor
.    x 1.312 =     34173.858 :: industry 2-weeks return factor
.    x 0.964 =     32959.646 :: "drift" penalty 1 days ago
.    x 0.964 =     31777.686 :: "drift" penalty 4 days ago
.    x 0.994 =     31596.356 :: overall "drift" factor
.    x 0.837 =     26440.894 :: largest single-day jump factor
.    x 0.092 =      2432.465 :: low price factor
.      x 1.0 =      2432.073 :: factor hist industry gain for week 15
.   cubeRoot =        13.448 :: reduced to standardize
.   - 18.419 =         0.474 :: add/subtract for performance
.                      0.474 :: FINAL WEIGHT for NASDAQ:AUPH


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org